LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

21 2.99

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.99

Максимум

21.11

Ключови измерители
By Trading Economics
Приходи	-29M -11M
Продажби	-24M 105M
EPS	-0.09
Марж на печалбата	-10.717
Служители	354
EBITDA	-31M -8.5M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+69.17% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-433M 2.5B
Предишно отваряне	18.01
Предишно затваряне	21

Настроения в новините

By Acuity

50%

148 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.42 / 14.93 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.05.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21.05.2026 г., 16:49 ч. UTC

Печалби

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21.05.2026 г., 16:26 ч. UTC

Значими двигатели на пазара

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21.05.2026 г., 23:37 ч. UTC

Печалби

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21.05.2026 г., 23:37 ч. UTC

Печалби

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21.05.2026 г., 23:37 ч. UTC

Печалби

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21.05.2026 г., 23:30 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

21.05.2026 г., 23:30 ч. UTC

Пазарно говорене

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21.05.2026 г., 22:33 ч. UTC

Придобивния, сливания и поглъщания

Conduent to Sell Public Transit Business to Modaxo for $164M

21.05.2026 г., 21:53 ч. UTC

Печалби

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21.05.2026 г., 21:02 ч. UTC

Печалби

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21.05.2026 г., 20:55 ч. UTC

Печалби

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21.05.2026 г., 20:30 ч. UTC

Горещи акции

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21.05.2026 г., 20:20 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

21.05.2026 г., 20:20 ч. UTC

Пазарно говорене

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21.05.2026 г., 20:20 ч. UTC

Печалби

Webull 1Q Adj EPS 3c >BULL

21.05.2026 г., 20:20 ч. UTC

Печалби

Webull 1Q Rev $159.9M >BULL

21.05.2026 г., 20:18 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Easing in Early May -- Market Talk

21.05.2026 г., 20:18 ч. UTC

Печалби

Webull 1Q Loss/Shr 4c

21.05.2026 г., 19:43 ч. UTC

Пазарно говорене

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21.05.2026 г., 19:33 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21.05.2026 г., 18:58 ч. UTC

Печалби

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21.05.2026 г., 18:15 ч. UTC

Пазарно говорене

Gold Higher For Second Consecutive Day -- Market Talk

21.05.2026 г., 17:40 ч. UTC

Пазарно говорене

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21.05.2026 г., 17:04 ч. UTC

Пазарно говорене

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21.05.2026 г., 17:01 ч. UTC

Печалби

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Stellantis Targets Distant but Constructive -- Market Talk

21.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

69.17% нагоре

12-месечна прогноза

Среден 34.63 USD 69.17%

Висок 36 USD

Нисък 33 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

148 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.